{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T22:42:02Z","timestamp":1791499322474,"version":"4.3.4"},"reference-count":25,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Pediatr"],"published-print":{"date-parts":[[2022,1,1]]},"DOI":"10.1001\/jamapediatrics.2021.4565","type":"journal-article","created":{"date-parts":[[2021,11,8]],"date-time":"2021-11-08T16:00:43Z","timestamp":1636387243000},"page":"34","source":"Crossref","is-referenced-by-count":52,"title":["Noninferiority and Safety of Nadolol vs Propranolol in Infants With Infantile Hemangioma"],"prefix":"10.1001","volume":"176","author":[{"given":"Elena","family":"Pope","sequence":"first","affiliation":[{"name":"Division of Pediatric Dermatology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Lara-Corrales","sequence":"additional","affiliation":[{"name":"Division of Pediatric Dermatology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cathryn","family":"Sibbald","sequence":"additional","affiliation":[{"name":"Division of Pediatric Dermatology, The Hospital for Sick Children, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Liy-Wong","sequence":"additional","affiliation":[{"name":"Division of Dermatology and Rheumatology, Children\u2019s Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nordau","family":"Kanigsberg","sequence":"additional","affiliation":[{"name":"Division of Dermatology and Rheumatology, Children\u2019s Hospital of Eastern Ontario, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth","family":"Drolet","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Wisconsin\u2013Madison"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin","family":"Ma","sequence":"additional","affiliation":[{"name":"Biostatistics Research Unit, University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"poi210066r1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1111\/bjd.2014.170.issue-4","article-title":"Prospective study of infantile hemangiomas: incidence, clinical characteristics and association with placental anomalies.","volume":"170","author":"Munden","year":"2014","journal-title":"Br J Dermatol"},{"issue":"7","key":"poi210066r2","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1001\/archderm.136.7.905","article-title":"Benign cutaneous vascular tumors of infancy: when to worry, what to do.","volume":"136","author":"Metry","year":"2000","journal-title":"Arch Dermatol"},{"issue":"5","key":"poi210066r3","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/pde.2005.22.issue-5","article-title":"Infantile hemangiomas: current knowledge, future directions. Proceedings of a research workshop on infantile hemangiomas, April 7-9, 2005, Bethesda, Maryland, USA.","volume":"22","author":"Frieden","year":"2005","journal-title":"Pediatr Dermatol"},{"issue":"24","key":"poi210066r4","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1056\/NEJMc0708819","article-title":"Propranolol for severe hemangiomas of infancy.","volume":"358","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2008","journal-title":"N Engl J Med"},{"issue":"8","key":"poi210066r5","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1056\/NEJMoa1404710","article-title":"A randomized, controlled trial of oral propranolol in infantile hemangioma.","volume":"372","author":"L\u00e9aut\u00e9-Labr\u00e8ze","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"poi210066r6","doi-asserted-by":"crossref","DOI":"10.1002\/prp2.496","article-title":"Pharmacokinetic variability of beta-adrenergic blocking agents used in cardiology.","volume":"7","author":"\u00c5gesen","year":"2019","journal-title":"Pharmacol Res Perspect"},{"issue":"1","key":"poi210066r7","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1111\/bjd.2015.172.issue-1","article-title":"Propranolol and central nervous system function: potential implications for paediatric patients with infantile haemangiomas.","volume":"172","author":"Langley","year":"2015","journal-title":"Br J Dermatol"},{"issue":"1","key":"poi210066r8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2165\/00003495-198020010-00001","article-title":"Nadolol: a review of its pharmacological properties and therapeutic efficacy in hypertension and angina pectoris.","volume":"20","author":"Heel","year":"1980","journal-title":"Drugs"},{"issue":"2","key":"poi210066r9","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/0163-7258(90)90092-G","article-title":"Beta-blockers and central nervous system side effects.","volume":"46","author":"McAinsh","year":"1990","journal-title":"Pharmacol Ther"},{"issue":"3","key":"poi210066r11","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/S0735-1097(10)80283-9","article-title":"Efficacy and safety of intravenous and oral nadolol for supraventricular tachycardia in children.","volume":"19","author":"Mehta","year":"1992","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"poi210066r12","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1097\/00004583-199706000-00021","article-title":"A pilot study of nadolol for overt aggression in developmentally delayed individuals.","volume":"36","author":"Connor","year":"1997","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"5-6","key":"poi210066r13","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1002\/jcph.1977.17.issue-5-6","article-title":"Metabolic studies in patients with nadolol: oral and intravenous administration.","volume":"17","author":"Dreyfuss","year":"1977","journal-title":"J Clin Pharmacol"},{"issue":"1","key":"poi210066r14","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1111\/bjd.2012.168.issue-1","article-title":"Expanding the therapeutic repertoire of infantile haemangiomas: cohort-blinded study of oral nadolol compared with propranolol.","volume":"168","author":"Pope","year":"2013","journal-title":"Br J Dermatol"},{"issue":"2","key":"poi210066r15","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1016\/j.jaad.2015.05.012","article-title":"Scoring the therapeutic effects of oral propranolol for infantile hemangioma: a prospective study comparing the hemangioma activity score (HAS) with the hemangioma severity scale (HSS).","volume":"73","author":"Janmohamed","year":"2015","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"poi210066r16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/archdermatol.2011.926","article-title":"Measuring the severity of infantile hemangiomas: instrument development and reliability.","volume":"148","author":"Haggstrom","year":"2012","journal-title":"Arch Dermatol"},{"issue":"5","key":"poi210066r17","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1111\/pde.12655","article-title":"Oral nadolol for the treatment of infantile hemangiomas: a single-institution retrospective cohort study.","volume":"32","author":"Randhawa","year":"2015","journal-title":"Pediatr Dermatol"},{"issue":"3","key":"poi210066r18","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-3866","article-title":"Efficacy of propranolol between 6 and 12 months of age in high-risk infantile hemangioma.","volume":"142","author":"Baselga","year":"2018","journal-title":"Pediatrics"},{"issue":"3","key":"poi210066r19","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1111\/bjd.14233","article-title":"Propranolol in the treatment of infantile haemangiomas: lessons from the European Propranolol In the Treatment of Complicated Haemangiomas (PITCH) taskforce survey.","volume":"174","author":"Wedgeworth","year":"2016","journal-title":"Br J Dermatol"},{"issue":"2","key":"poi210066r20","doi-asserted-by":"publisher","first-page":"e259","DOI":"10.1542\/peds.2010-0029","article-title":"A randomized controlled trial of propranolol for infantile hemangiomas.","volume":"128","author":"Hogeling","year":"2011","journal-title":"Pediatrics"},{"issue":"4","key":"poi210066r21","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2016-0353","article-title":"Safety of oral propranolol for the treatment of infantile hemangioma: a systematic review.","volume":"138","author":"L\u00e9aute-Labr\u00e8ze","year":"2016","journal-title":"Pediatrics"},{"issue":"2","key":"poi210066r22","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/pde.v38.2","article-title":"Propranolol\u2019s effects on the sleep of infants with hemangiomas: a prospective pilot study.","volume":"38","author":"Frost","year":"2021","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"poi210066r23","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1111\/pde.2015.32.issue-6","article-title":"Oral nadolol for children with infantile hemangiomas and sleep disturbances with oral propranolol.","volume":"32","author":"Bernabeu-Wittel","year":"2015","journal-title":"Pediatr Dermatol"},{"issue":"1","key":"poi210066r24","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1542\/peds.2012-1691","article-title":"Initiation and use of propranolol for infantile hemangioma: report of a consensus conference.","volume":"131","author":"Drolet","year":"2013","journal-title":"Pediatrics"},{"key":"poi210066r25","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/2728952","article-title":"Propranolol treatment for infantile hemangiomas: short-term adverse effects and follow-up to age two.","volume":"2019","author":"Li","year":"2019","journal-title":"Biomed Res Int"},{"key":"poi210066r10","volume-title":"Drug Class Review on Beta Adrenergic Blockers","author":"Helfand","year":"2005"}],"container-title":["JAMA Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/articlepdf\/2786019\/jamapediatrics_pope_2021_oi_210066_1643666793.06807.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,31]],"date-time":"2022-01-31T22:30:25Z","timestamp":1643668225000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamapediatrics\/fullarticle\/2786019"}},"subtitle":["A Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamapediatrics.2021.4565","relation":{},"ISSN":["2168-6203"],"issn-type":[{"value":"2168-6203","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1,1]]}}}